BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
SUBSCRIBE
BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
BullScope
No Result
View All Result
Home Bargains & Bubbles

PepsiCo: The Stock Is Priced for Doubt. The Filing Tells a Different Story.

Moe Alsumidaie, MBA, MSF by Moe Alsumidaie, MBA, MSF
August 5, 2026
in Bargains & Bubbles
0
74
SHARES
1.2k
VIEWS
Share on XShare on LinkedInShare on Facebook

For most of the last decade, owning PepsiCo felt like owning a toll road. Revenue climbed steadily, the dividend arrived like clockwork, and the stock traded at a premium that reflected how much investors valued predictability. Then came 2025. An activist investor arrived, price cuts followed, the stock fell, and by this August the shares sit nearly 20% below their 52-week high. The toll road suddenly looks like a construction zone. The question the filed numbers raise is whether the damage is structural or cosmetic.

That gap between what the business is actually doing and what the stock price implies is what we call the tension between “the math” (what filed fundamentals justify) and “the mood” (what the market is currently paying). Right now, those two readings are unusually far apart, and that distance is the story.

In one breath

PepsiCo’s most recent quarter showed revenue growing and operating profit more than doubling year-over-year, yet the stock trades at its lowest earnings multiple in at least a decade. The market is pricing the company as if its best years are behind it. The filed numbers do not obviously agree. The open question is whether North America’s stumble is a detour or a destination.

How a Snack Giant Ended Up Here

PepsiCo spent the early 2020s buying its way into faster-growing categories. It paid $3.85 billion for Rockstar Energy, took a meaningful stake in Celsius, and then in early 2025 added Siete Foods and prebiotic soda brand Poppi for a combined sum exceeding $3 billion. The logic was straightforward: traditional soda and chips were slowing, so buy the brands that younger consumers were already reaching for.

BullScope TerminalWant the full evidence sheet behind pieces like this?The terminal runs the complete workup: PepsiCo and 500+ other names, on the same official data.See the evidence engine →

But by late 2025, the core business was visibly straining. Consumers, squeezed by years of inflation, were trading down or buying less. Elliott Investment Management, an activist investor (a shareholder who buys a stake specifically to push for strategic changes), arrived and pushed for a reset. PepsiCo responded by cutting its U.S. product lineup by nearly a fifth and then slashing prices on Lay’s and Doritos by double digits. The bet was that lower prices would bring volume back. It worked, partially. North America Foods volume turned positive in Q1 2026. Then in Q2 it slipped again.

For anyone watching the stock, that Q2 stumble landed hard. Shares fell roughly 5% on July 9, 2026, their worst single day since April 2025, after the company disclosed a slight organic revenue decline in North America for the quarter. The mood soured fast.

What the Filing Actually Shows

The 10-Q for the quarter ended June 13, 2026 tells a more complicated story than the stock reaction suggested. Total net revenue for the quarter was $24.2 billion, up 6.4% from a year earlier. Operating income, the profit left after running the business but before interest and taxes, more than doubled year-over-year. Diluted earnings per share jumped sharply, though much of that reflects a weak comparison period in 2025.

The geographic picture matters here. International was the engine: Asia Pacific foods volume grew at a double-digit pace, and the company’s international franchise beverage business posted strong revenue gains. North America was the drag. Convenient foods revenue fell even as the company gained volume share, meaning it sold more units but at lower prices. That is the direct consequence of the price-cut strategy: more bags sold, less revenue per bag.

Zoom out to the full fiscal year 2025, and the picture is steadier than the recent noise implies. The 10-K for fiscal year ended December 27, 2025 shows net revenue of $93.9 billion, free cash flow of $8.2 billion, and dividends paid of $7.6 billion. A business generating that much free cash flow and returning nearly all of it to shareholders is not obviously broken. It is, however, clearly slower than it was.

BullScope TerminalYou just read PepsiCo’s filed numbers.Every claim above traces to a filing. Run any of 500+ companies through the same math-vs-mood engine. Free tier available.Open the Terminal →

The Arithmetic of the Discount

Here is where the math-versus-mood tension becomes concrete. Our data shows PepsiCo’s price-to-earnings ratio, the price tag per dollar of annual profit, sitting well below its decade median. On a price-to-sales basis, the stock is at its sixth percentile of its own history, meaning it has been cheaper relative to revenue only 6% of the time over the past decade. A business trading near the bottom of its own historical range is either genuinely impaired or genuinely cheap. The filed numbers do not settle that question, but they do define it.

The dividend yield of 4.27% as of August 5, 2026, is worth pausing on. PepsiCo paid out billions in dividends in fiscal 2025 and has guided for more in 2026. A yield above 4% on a company that has raised its dividend for decades is the market saying it needs to be compensated for uncertainty. That is the mood talking.

Commentary in the market reflects the split. Seeking Alpha contributor Dividend Power, writing on July 12, 2026, described the stock as undervalued relative to estimated 2026 non-GAAP earnings, well below what he characterized as the five-year average multiple. But TIKR.com reported on July 27, 2026 that only three of 22 analysts covering the stock issued buy ratings, with sixteen recommending hold. The professional consensus is not pessimistic so much as patient, waiting to see whether the North America recovery holds.

The Thing the Numbers Cannot Settle

What the filings cannot tell us is whether the North America weakness is a hangover from the price-cut transition or something more durable. Consumer staples companies, businesses selling things people buy out of habit rather than excitement, tend to recover when pricing stabilizes. But they can also enter long slow declines when habits change. Poppi and Siete are bets that PepsiCo can own the next generation of habits. Whether those acquisitions are enough to move the needle on a nearly $94 billion revenue base is a fair question, and the data does not yet answer it.

The FY2025 net margin of 8.8%, down from 10.4% in FY2024 per our data, reflects the cost of the reset: price cuts, restructuring, and the integration of new brands all compress margins in the short term. Whether margins recover toward the range they held for most of the prior five years is the number to watch in the filings ahead.

BullScope TerminalPepsiCo was the article. The engine is the product.Same yardsticks, any ticker: filed financials in, math-vs-mood out. Nothing here is advice; it is the evidence, organized.Run another company →

Reading the Numbers

  • Q2 2026 net revenue: $24.2 billion, up 6.4% year-over-year. This is the total sales figure for the quarter ending June 13, 2026, per the 10-Q filed July 8, 2026. A 6.4% gain means for every $100 in sales a year ago, the company collected $106.40 this quarter. It matters because the stock fell on this report, suggesting the market focused on the North America weakness rather than the headline growth.
  • FY2025 free cash flow: $8.2 billion. Free cash flow is the money left after the company pays for its own upkeep and investment, the cash it can actually distribute or deploy. At $8.2 billion, per the Q4 2025 earnings release, PepsiCo generated roughly $6 for every share outstanding. The company returned most of that to shareholders via dividends. A household earning $80,000 and spending $76,000 on its mortgage and bills would have the same ratio.
  • P/S ratio: 2.0 times, at the sixth percentile of its own decade. Price-to-sales compares the stock’s total market value to annual revenue. At 2.0 times, per our data, the market is paying $2 for every $1 of annual sales, near the cheapest it has been in ten years. For context, the decade median is 2.7 times. If a coffee shop normally sold for 2.7 times its annual revenue and today it sold for 2.0 times, you would want to know whether the business changed or just the asking price.
  • Dividend yield: 4.27% as of August 5, 2026. This means a holder of $10,000 in stock receives roughly $427 per year in dividends, per Stock Analysis data. For a consumer staples company, a yield above 4% is historically high and signals that the market is skeptical about growth, not about the dividend’s safety.
  • FY2025 net margin: 8.8%, versus 10.4% in FY2024. Net margin is what survives of each dollar of sales after every bill is paid. The 1.6 percentage point drop, per our data from the FY2025 10-K, means the company kept $8.80 of every $100 in sales last year, down from $10.40 the year before. On $94 billion in revenue, that difference is roughly $1.5 billion in profit. Whether this is a one-year reset cost or a new normal is the margin question the next two filings will begin to answer.

Reading the numbers

$24.2 billion in quarterly revenue, up 6.4% year-over-year. Revenue is the simplest measure of how much business a company is doing: every bag of chips and bottle of Pepsi sold in the quarter adds to this line. A 6.4% increase means the company collected $6.40 more for every $100 it took in a year ago. This number matters to the story because the stock dropped sharply on the same report that contained it. The market was not reacting to the headline; it was reacting to the fact that North America, the company’s home market, shrank slightly even as the global total grew. The gap between those two numbers is the entire tension of the article: a company that looks fine from altitude and troubled up close.

$8.2 billion in free cash flow for fiscal year 2025. Free cash flow is what remains after a company has paid all its operating costs and made the investments needed to keep the business running. It is the cash that can actually be handed to shareholders or used to pay down debt. PepsiCo generated roughly $6 per share in spendable cash last year, and it returned nearly all of it as dividends. This figure anchors the bull case: a business producing that much real cash is not obviously broken, whatever the stock price implies. The household analogy in the article holds: earning $80,000 and spending $76,000 on fixed obligations leaves very little margin for error, but it is not insolvency.

P/S ratio of 2.0 times, at the sixth percentile of its own ten-year history. Price-to-sales divides the stock’s total market value by annual revenue. At 2.0 times, investors are paying $2 for every $1 of yearly sales, near the cheapest valuation PepsiCo has carried in a decade, when the normal range has been closer to 2.7 times. This number is load-bearing because it quantifies the mood discount. It does not say the stock is cheap in an absolute sense; it says the market is applying an unusually large haircut to a business whose revenue is still growing. Whether that haircut reflects genuine structural damage or temporary pessimism is the question the article leaves open, and the one the next several quarterly filings will begin to answer.

Sources

  • PepsiCo 10-Q, quarter ended June 13, 2026 (SEC EDGAR)
  • PepsiCo 10-K, fiscal year ended December 27, 2025 (SEC EDGAR)
  • PepsiCo Q4 2025 earnings release
  • PepsiCo Q2 2026 earnings release
  • Seeking Alpha / TIKR.com analyst coverage summary, July 27, 2026
  • Stock Analysis: PepsiCo statistics including dividend yield
  • Full Ratio: PepsiCo trailing P/E ratio
  • History Oasis: PepsiCo acquisitions history
BullScope publishes impersonal research for a general audience. Nothing here is personalized investment advice, and nothing here is a recommendation to buy or sell any security. As of publication, neither BullScope nor its operator holds a position in any security, covered or otherwise; we do not trade at all, and we accept no compensation from any company we cover. When a conflict of interest exists, we do not publish: companies that compensate our operator in any capacity, or about which our operator could hold nonpublic information, are barred from coverage automatically, as described in the conflicts policy in our methodology. Figures come from company filings and public data through our published methodology; forecasts are conditional scenarios, not predictions and not promises. Markets carry risk, including loss of principal. Consider your own situation, or consult a licensed adviser, before acting on anything you read.
BullScope TerminalYou just read PepsiCo’s filed numbers.Every claim above traces to a filing. Run any of 500+ companies through the same math-vs-mood engine. Free tier available.Open the Terminal →
Moe Alsumidaie, MBA, MSF

Moe Alsumidaie, MBA, MSF

Moe Alsumidaie, MBA, MSF is the Chief Editor of BullScope. Trained in finance, with a Master of Science in Finance and an MBA, he spent years inside large public healthcare companies including Abbott, Genentech, and Roche, learning how the businesses behind the filings actually run. As a journalist and Chief Editor of The Clinical Trial Vanguard, his reporting has appeared in Applied Clinical Trials, The American Journal of Managed Care, and CNET, and has been cited in U.S. Supreme Court proceedings. At BullScope he brings those disciplines together: every note starts in the SEC filings, runs through published methodology, and shows its work.

Recommended For You

Halozyme: The Royalty Machine Trading at a Premium to Its Own History

by Moe Alsumidaie, MBA, MSF
September 9, 2026
0

Six years ago, Halozyme Therapeutics was a mid-sized biotech with a clever idea and a thin income statement. The idea was ENHANZE, a drug-delivery technology that dissolves the...

Read moreDetails

Merck Is Printing Money and Losing Money at the Same Time. Both Are True.

by Moe Alsumidaie, MBA, MSF
September 7, 2026
0

A trailing price-to-earnings ratio of 120 sits next to a price-to-sales ratio near its highest point in a decade. Those two numbers describe the same stock on the...

Read moreDetails

A $2.4 Billion Question: What Sarepta’s Filed Numbers Actually Say

by Moe Alsumidaie, MBA, MSF
September 3, 2026
0

The gist of it Sarepta's filed numbers tell a story of a company that briefly turned profitable in 2024, then swung back to a loss in 2025 after...

Read moreDetails

The Quiet Compounder at a Loud Price: What Royalty Pharma’s Filings Actually Say

by Moe Alsumidaie, MBA, MSF
September 2, 2026
0

Royalty Pharma's stock sat at an all-time low in December 2024. By late August 2026, it had touched an all-time high above $62. That is a gain of...

Read moreDetails

Half the Price, Same Business: What Zoetis’s Filed Numbers Actually Say

by Moe Alsumidaie, MBA, MSF
August 31, 2026
0

Two years ago, Zoetis traded at roughly 35 times its annual earnings. Today it trades at roughly 12 times. The revenue line has kept growing. The margin line...

Read moreDetails
Next Post

The Pessimist's Discount: What P&G's Price Assumes, and What the Filings Say

Please login to join discussion
BullScope
The Research Terminal
Run any stock through the BullScope evidence engine. Filings in, evidence out. Every number explains itself.
Open the Terminal
A BullScope product

Related News

Evidence Sheet: UnitedHealth Group (UNH)

September 4, 2026

The Headline Said “Cooling.” The Data Said “Complicated.”

August 18, 2026

Viatris: The Stock Is Up 55% in a Year. The Revenue Has Fallen Every Year Since 2021.

September 8, 2026
BullScope

BullScope is an evidence-first investment research publication. Every note starts in the filings: what companies actually report, what the market assumes, and where the two disagree. We read the numbers so you can read the story. Not investment advice.

Prefer BullScope.ai on Google

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

No Result
View All Result
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

Not enough quota to unlock this post
Unlock left : 0
Are you sure want to cancel subscription?
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.